{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:41:39Z","timestamp":1788316899942,"version":"build-2803163510"},"reference-count":66,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,3,23]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment settings is increasing rapidly. Although some patients will experience durable benefit, many have either no clinical response or see their disease progress following an initial response to therapy. There is a significant need to identify therapeutic approaches to overcome resistance and confer clinical benefits for these patients. PD-1 pathway blockade has the longest history of use in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Therefore, these settings also have the most extensive clinical experience with resistance. In 2021, six non-profit organizations representing patients with these diseases undertook a year-long effort, culminating in a 2-day workshop (including academic, industry, and regulatory participants) to understand the challenges associated with developing effective therapies for patients previously exposed to anti-PD-(L)1 agents and outline recommendations for designing clinical trials in this setting. This manuscript presents key discussion themes and positions reached through this effort, with a specific focus on the topics of eligibility criteria, comparators, and endpoints, as well as tumor-specific trial design options for combination therapies designed to treat patients with melanoma, NSCLC, or RCC after prior PD-(L)1 pathway blockade.<\/jats:p>","DOI":"10.1136\/jitc-2022-006555","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:00:29Z","timestamp":1683111629000},"page":"e006555","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Addressing resistance to PD-1\/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03991130","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03833440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05068427","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03385486","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05061134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04250246","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04987203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03793166","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-3531","authenticated-orcid":false,"given":"Tian","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Forde","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-9719","authenticated-orcid":false,"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Barksdale","sequence":"additional","affiliation":[{"name":"LUNGevity Foundation, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Selig","sequence":"additional","affiliation":[{"name":"WSCollaborative, McLean, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot","family":"Ebbinghaus","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Fusaro","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Co Summit, Summit, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"Gunenc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Battle","sequence":"additional","affiliation":[{"name":"Kidney Cancer Research Alliance, Alexandria, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Burns","sequence":"additional","affiliation":[{"name":"Melanoma Research Foundation, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Hurlbert","sequence":"additional","affiliation":[{"name":"Melanoma Research Alliance, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stewart","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-9924","authenticated-orcid":false,"given":"Michael B","family":"Atkins","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"2025100314494912000_11.5.e006555.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2025100314494912000_11.5.e006555.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"2025100314494912000_11.5.e006555.3","unstructured":"Opportunities for combination drug development. 2019. Available: https:\/\/www.focr.org\/sites\/default\/files\/pdf\/Combo_Drug_Development_Whitepaper.pdf"},{"key":"2025100314494912000_11.5.e006555.4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100314494912000_11.5.e006555.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100314494912000_11.5.e006555.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025100314494912000_11.5.e006555.7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100314494912000_11.5.e006555.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"2025100314494912000_11.5.e006555.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"2025100314494912000_11.5.e006555.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025100314494912000_11.5.e006555.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100314494912000_11.5.e006555.12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (checkmate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025100314494912000_11.5.e006555.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"2025100314494912000_11.5.e006555.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2025100314494912000_11.5.e006555.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.004"},{"key":"2025100314494912000_11.5.e006555.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2025100314494912000_11.5.e006555.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.033"},{"key":"2025100314494912000_11.5.e006555.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"2025100314494912000_11.5.e006555.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.05.014"},{"key":"2025100314494912000_11.5.e006555.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.4.2278"},{"key":"2025100314494912000_11.5.e006555.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3271"},{"key":"2025100314494912000_11.5.e006555.22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025100314494912000_11.5.e006555.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2025100314494912000_11.5.e006555.24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1223"},{"key":"2025100314494912000_11.5.e006555.25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-cancerbio-070220-111016","article-title":"Central role of the antigen-presentation and interferon-\u03b3 pathways in resistance to immune checkpoint blockade","volume":"6","author":"Paschen","year":"2022","journal-title":"Annu Rev Cancer Biol"},{"key":"2025100314494912000_11.5.e006555.26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/iai.64.2.569-575.1996","article-title":"Influence of beta 2-microglobulin expression on gamma interferon secretion and target cell lysis by intraepithelial lymphocytes during intestinal Listeria monocytogenes infection","volume":"64","author":"Emoto","year":"1996","journal-title":"Infect Immun"},{"key":"2025100314494912000_11.5.e006555.27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114984"},{"key":"2025100314494912000_11.5.e006555.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30513-3"},{"key":"2025100314494912000_11.5.e006555.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"2025100314494912000_11.5.e006555.30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100314494912000_11.5.e006555.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2151"},{"key":"2025100314494912000_11.5.e006555.32","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2025100314494912000_11.5.e006555.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065"},{"key":"2025100314494912000_11.5.e006555.34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"2025100314494912000_11.5.e006555.35","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000408"},{"key":"2025100314494912000_11.5.e006555.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025100314494912000_11.5.e006555.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2025100314494912000_11.5.e006555.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3065"},{"key":"2025100314494912000_11.5.e006555.39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4746"},{"key":"2025100314494912000_11.5.e006555.40","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.32951","article-title":"Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer","volume":"147","author":"Hellmann","year":"2020","journal-title":"Int J Cancer"},{"key":"2025100314494912000_11.5.e006555.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2025100314494912000_11.5.e006555.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"2025100314494912000_11.5.e006555.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"2025100314494912000_11.5.e006555.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1"},{"key":"2025100314494912000_11.5.e006555.45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.annonc.2022.04.450","article-title":"Deciphering radiological stable disease to immune checkpoint inhibitors","volume":"33","author":"Luo","year":"2022","journal-title":"Ann Oncol"},{"key":"2025100314494912000_11.5.e006555.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.011"},{"key":"2025100314494912000_11.5.e006555.47","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jtho.2021.01.299","article-title":"OA07.08 Hudson: an open-label, multi-drug, biomarker-directed, phase II platform study in patients with NSCLC, who progressed on anti-PD (L) 1 therapy","volume":"16","author":"Besse","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100314494912000_11.5.e006555.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.10.001"},{"key":"2025100314494912000_11.5.e006555.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2025100314494912000_11.5.e006555.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2025100314494912000_11.5.e006555.51","doi-asserted-by":"crossref","first-page":"S1429","DOI":"10.1016\/j.annonc.2021.10.139","article-title":"120O pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS \u22651 % (LEAP-007): a phase III, randomized, double-blind study","volume":"32","author":"Yang","year":"2021","journal-title":"Annals of Oncology"},{"key":"2025100314494912000_11.5.e006555.52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4596","article-title":"PROSPER: phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143)","volume":"39","author":"Allaf","year":"2021","journal-title":"JCO"},{"key":"2025100314494912000_11.5.e006555.53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"2025100314494912000_11.5.e006555.54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"2025100314494912000_11.5.e006555.55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100314494912000_11.5.e006555.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2025100314494912000_11.5.e006555.57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011"},{"key":"2025100314494912000_11.5.e006555.58","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIb or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"2025100314494912000_11.5.e006555.59","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1200\/JCO.21.01701","article-title":"Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma","volume":"40","author":"Pires da Silva","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100314494912000_11.5.e006555.60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100314494912000_11.5.e006555.61","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9597","article-title":"Combining ipilimumab (IPI) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)","volume":"36","author":"Vanderwalde","year":"2018","journal-title":"JCO"},{"key":"2025100314494912000_11.5.e006555.62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041027","article-title":"Primary resistance to PD-1-based immunotherapy-A study in 319 patients with stage IV melanoma","volume":"12","author":"Amaral","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100314494912000_11.5.e006555.63","doi-asserted-by":"crossref","first-page":"356154","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial\u2014ECOG-ACRIN EA6134","volume":"39","author":"Atkins","year":"2021","journal-title":"JCO"},{"key":"2025100314494912000_11.5.e006555.64","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical outcomes from the phase 3 checkmate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"JCO"},{"key":"2025100314494912000_11.5.e006555.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"2025100314494912000_11.5.e006555.66","unstructured":"Guidance for industry: codevelopment of two or more new investigational drugs for use in combination. n.d. Available: https:\/\/www.fda.gov\/media\/80100\/download"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:50:02Z","timestamp":1759528202000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":66,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,3]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/jitc-2022-006555"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006555","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}